Access To Medical Treatments (Innovation) Bill
About these Parliamentary proceedings
Reference
605 cc529-552 Session
2015-16Legislative stage
Report stageChamber / Committee
House of Commons chamberRelated items
Wednesday, 24 June 2015
Bills
House of Commons
Proceeding contributions
I beg to move, That the clause be read a Second time.
With this it will be convenient to discuss the following:
New clause 2—Identifying evidence...
Show all contributions (31)
These new clauses and amendments, which I support, relate to off-patent drugs. I think it would b...
I congratulate my hon. Friend on the excellent work he has done on the Off-patent Drugs Bill. Giv...
I am grateful to my hon. Friend for that intervention. I hope to hear such a commitment today, so...
Members may be aware that unlike the initial stages of my Bill, the journey of the Off-patent Dru...
I congratulate my hon. Friend the Member for Daventry (Chris Heaton-Harris) on his success in bri...
I rise to support new clauses 1 to 3, 5 and 6 and amendments 10 and 13. The only reason new claus...
It is with great pleasure that I rise to speak in support of this important Bill, introduced by m...
I thank my hon. Friend the Member for Daventry (Chris Heaton-Harris) for bringing this important ...
I congratulate the hon. Member for Daventry (Chris Heaton-Harris) on navigating the Bill to this ...
Order. The hon. Lady had wished to contribute but toddled out of the Chamber at the appropriate m...
Very briefly, Mr Speaker.
I support the Bill and commend all those who have worked towards ...
It is a great pleasure to take part in the debate and to support a package of amendments that hav...
I would just like to make two points. First, the “British National Formulary” is UK-wide. Secondl...
The hon. Gentleman makes two good points. This is, of course, UK-wide. One of the challenges, as ...
We have moved on from talking about the BNF. I accept the comments about listing groups that woul...
The hon. Lady makes an important point about the classification of different drugs available to c...
I accept the Minister’s points, but my concern remains that if in 10 years we have simvastatin in...
The hon. Lady makes an interesting, important and useful point that I undertake to pick up in our...
I am grateful to Members across the House for their contributions and to the Life Sciences Minist...
We now come to amendment 1—
On a point of order, Mr Deputy Speaker. I am unsure of the process. What happened to amendment 13...
It comes later. It is about three pages further on in the dossier. It has not been lost, and we w...
I beg to move amendment 1, page 1, leave out lines 7 to 9.
With this it will be convenient to discuss the following:
Amendment 11, page 1, line 18, in...
I just thought I would check about amendment 13, Mr Deputy Speaker. This whole experience has bee...
Does the hon. Gentleman understand the danger of undermining our clinical trials systems, in that...
The hon. Lady knows that I would obviously have preferred to retain clauses 3 and 4, but I have t...
I support my hon. Friend’s amendment 2, which would remove clause 3—the responsible innovation cl...